By Pooja Toshniwal PahariaDec 20 2022Reviewed by Danielle Ellis, B.Sc. In a recent study published in the Journal of the American College of Cardiology, researchers compared the prognosis of myocarditis developing after BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccination with viral myocarditis over six months.
About the study In the present territory-wide retrospective cohort study, researchers examined the probable prognostic differences between individuals diagnosed with myocarditis following BNT162b2 vaccinations and individuals diagnosed with viral illness-associated myocarditis. Other individuals diagnosed with myocarditis between 1 January 2000 and 31 December 2019 were assessed for being allotted to the viral illness-associated myocarditis group for comparative evaluation. The diagnosis of myocarditis and the prognostic outcomes were based on the international classification of diseases, ninth clinical modification codes.
Results By 31 March 2022, 8,896,843 BNT162b2 vaccine doses were administered to 3,979,103 patients of 12 years and above in Hong Kong. Between 1 January 2000 and 31 December 2019, 1,483 myocarditis cases were documented, of which 119 cases were of post-BNT162b2 vaccination myocarditis. After applying the eligibility criteria, 866 individuals were considered for the final analysis, comprising 104 patients with post-mRNA COVID-19 vaccination myocarditis and 762.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: Daily_Record - 🏆 9. / 89 Read more »
Source: i newspaper - 🏆 8. / 89 Read more »
Source: bbcemt - 🏆 120. / 51 Read more »
Source: HuffPostUK - 🏆 108. / 51 Read more »